# NCT06291987 (NCT06291987)

> Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation

No report yet. It can be ordered.

- Drugs tested: ivosidenib plus ruxolitinib
- Indication: IDH1-mutated advanced-phase myeloproliferative neoplasms

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06291987
- Phase: PHASE1
- Status: RECRUITING
- Sponsor: University of Chicago
- Conditions: Myeloproliferative Neoplasms
- Interventions: Ivosidenib; Ruxolitinib
- Enrollment: 18
- Primary outcome: Maximum tolerated dose

## Indexed commentary on NCT06291987 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- Bluesky threads: 19

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=nct06291987

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06291987", "email": "<work email>"}; the inbox owner confirms by the emailed link.